Bristol Myers Squibb (BMS) announces the appointment of Sally Ann McNab as General Manager for Belgium, Luxembourg and The Netherlands, effective September 1st. Previously she was Vice President Worldwide Oncology Commercialisation at BMS.
Sally Ann McNab takes on the general management of the Benelux organisation of the global biopharmaceutical company Bristol Myers Squibb. In her previous role as Vice President Worldwide Oncology Commercialisation at BMS, Sally Ann focused on delivering a comprehensive Global Oncology Pan Tumor Commercialisation strategy across all tumor indications, assets and geographies to drive and innovate in the Oncology solid tumor Franchise, making a difference for cancer patients worldwide. This included amongst others the co-creation of a holistic Pan Tumor ESOC (Earlier Stages of Cancer) Commercial Strategy through a cross-functional core team of Commercial, Medical and Communications.
Sally Ann McNab: “I’m excited to take on this new adventure and I’m looking forward to moving to Belgium and being with the Belgium and Netherlands teams in person. There is such a bright future ahead for the Benelux organisation and I feel absolutely honoured to be part of it. I can’t wait to work with the teams and continue to shape the happy, healthy and fun place to work that BMS is. I also look forward to meeting our external partners and further develop the cooperation with them. Together, we are stronger. Together we can do more for patients - beyond the discovery, development and delivery of medicines.”
Prior to joining BMS, Sally Ann worked at GSK in various Commercial Leadership roles across multiple Therapeutic Areas including Immunology, Respiratory and Vaccines. Sally Ann obtained an MBA at the Henley Management College (UK) and holds a Bachelor of Science Honours Biochemistry from London University as well as a Masters’ degree in Strategic Change and Business Transformation from Oxford University.
A seasoned pharmaceutical expert with an international track record, Sally Ann will continue to drive forward the positioning of BMS in the Benelux, a strategically well-placed region in the heart of Europe where BMS strives to develop its diversified portfolio and deliver innovative medicines across the company’s key therapeutic areas: Oncology, Hematology, Cardiovascular and Immunology. BMS has been active in Belgium and Luxembourg for more than 40 years, and in The Netherlands for over 50 years. Every day, the Benelux team works together for patients with solid and blood cancers, heart diseases and autoimmune diseases. Through more than 200 active clinical trials, BMS ensures that patients in Belgium, Luxembourg and The Netherlands have access to the most promising new medicines.